El interés en corto de Structure Therapeutics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Structure Therapeutics. Los datos de interés en corto se actualizan cada dos semanas.

Structure Therapeutics (NASDAQ:GPCR) Bolsa, Informe de interés en corto

Structure Therapeutics

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.

Structure Therapeutics Inc. - American Depositary Shares

Structure Therapeutics Inc

News

AMZN

Amazon Drivers At DBK4 Facility In New York Join Teamsters Union

Raymond James analyst Josh Beck initiates coverage on MercadoLibre (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) with a Outperform rating and announces Price Target of $2350.

Price Target

Initiation

Analyst Ratings

MELI

Raymond James Initiates Coverage On MercadoLibre with Outperform Rating, Announces Price Target of $2350

Shares of Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) dropped more than 10% Thursday following a report that the Department of Justice is investigating the company <a href="https://www.benzinga.com/topic/semiconductors">for potential accounting violations</a>. The stock, once a high-flyer during the AI market surge, has now plunged over 60% from its peak. But, shares rebounded Friday, trading up 4.6% to $421.32 a share at the time of publication. <a href="https://www.benzinga.com/premarket-prep">Benzinga PreMarket Prep</a> hosts, professional traders Joel Elconin and Dennis Dick, discussed the move on Friday's episode of the show. 
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Super Micro Computer Stock Falls On Report Of DOJ Probe &#x7C; $SMCI" width="500" height="281" src="https://www.youtube.com/embed/ENNx8d_piHM?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
"It bounced where it needed to bounce," <a href="https://www.youtube.com/watch?v=ENNx8d_piHM">Dick said.</a> "You got to $382, you did undercut it at $373, but you quickly got back above that… I think it's an overshoot to be honest… there's a lot of things we don't know, a lot of headline risk, but I think $373 from yesterday is safe." Elconin called the situation &#8220;convoluted,&#8221; pointing to the uncertainty regarding the accounting situation. The DOJ's probe comes after a Hindenburg Research short report on the company, which also alleged accounting malpractices. Read Also: <a href="https://www.benzinga.com/news/24/09/41052423/super-micro-computer-stock-falls-on-report-of-doj-probe-what-to-know">Super Micro Computer Stock Falls On Report Of DOJ Probe: What To Know </a><a href="https://www.benzinga.com/news/24/09/41052423/super-micro-computer-stock-falls-on-report-of-doj-probe-what-to-know"> </a>But, the PreMarket Prep hosts pointed out the market's tendency to overreact to news headlines, which could help explain Friday's bounce. Super Micro Computer's stock had already declined following the release of Hindenburg Research's short report in late August, meaning that some of the negative news could have already been priced in. Super Micro Computer's decline on Thursday came while other chip stocks rallied following strong quarterly results from Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>). The iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>), which tracks some of the biggest names in the sector, closed up more than 3.5% Thursday, while SMCI's stock closed down 12%. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41068393/inflation-decline-strengthens-confidence-in-feds-interest-rate-cut-if-you-were-second-guessing-the-f">Inflation Decline Strengthens Confidence In Fed&#8217;s Interest Rate Cut: &#8216;If You Were Second Guessing The Fed&#8230; You Aren&#8217;t Now&#8217;</a></li>
</ul>
Photo: Shutterstock

Exclusives

Tech

SMCI

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

Is SMCI's Big Drop A Warning Sign Or Buying Opportunity? Here's What Professional Traders Say

Carvana Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cvna#NYSE">CVNA</a>) is one of the best-performing retail stocks in 2024, up more than 230% as markets closed on September 24, 2024. This continues a run that started in late 2023 that has sent the stock up by more than 317%. The company is known for its &quot;vending machine&quot; approach to car buying that has been disruptive to the traditional used car buying process. &nbsp;
In the last two quarters, the company has returned to growth, albeit with unit sales growing more than revenue. This suggests that consumer demand remains strong, albeit perhaps at lower price points. &nbsp;&nbsp;
So, if lower interest rates bring down interest rates as expected, then the sky&#39;s the limit for CVNA stock, right? That&#39;s what the conventional wisdom may say, but analysts aren&#39;t so sure, with some believing that all the growth in CVNA stock is already priced in. &nbsp;
The Carvana analyst forecasts on MarketBeat have a consensus price target of $153.88, which would be a 10.4% pullback for the stock. However, in September, three analysts reiterated or increased their price targets for CVNA stock at levels far above the consensus price, with the highest coming in at $200. &nbsp;
<h2>Lower Interest Rates May Stimulate Pent-Up Demand&nbsp;</h2>
Used car prices have come down, but they can&#39;t go low enough to spark demand from consumers who have two concerns. First, they&#39;re still dealing with inflation in their daily lives. This is particularly true for low- and middle-income consumers.
As noted above, bulls will point out that in Carvana&#39;s July 2024 earnings report, the company showed unit sales rising more than revenue and a higher profit per vehicle sale than its competitors. The company did post earnings per share of 14 cents, which beat expectations by 14 cents. &nbsp;
However, this shows that Carvana was selling lower-priced cars and, more than likely, to consumers with damaged credit. That leads to the second investor concern. Many of these consumers, and certainly lenders like Ally, are concerned about the safety of their jobs. &nbsp;
<h2>Ally Warns of Rising Auto Loan Delinquencies, Impacting Carvana</h2>
Most used car dealers rely on third parties to buy their auto loans.&nbsp;Carvana&#39;s largest partner is&nbsp;Ally Financial Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ally#NYSE">ALLY</a>),&nbsp;which has agreed to buy $4 billion of Carvana receivables. That buying activity began in January 2024 and runs through January 10, 2025. &nbsp;
However, in September, Ally warned that loan delinquencies in retail auto sales were rising, including late-stage delinquencies (those longer than 60 days). This is the first step towards repossession, and Ally forecasts that the situation will only worsen. Remember, these loans come with a fixed rate, so current borrowers won&#39;t get relief from lower rates. &nbsp;
The loans themselves don&#39;t pose a risk to Carvana. But if the situation doesn&#39;t improve, Ally will demand better terms on future loans, which will eat into Carvana&#39;s margins and, ultimately, its earnings.&nbsp;&nbsp;
<h2>The Cost of Growth Doesn&#39;t Allow for Selectivity&nbsp;</h2>
Investors should also bear in mind that Carvana continues to pay down the debt that fueled its growth. In the last quarter it had $5.4 billion in long-term debt and servicing that debt will eat into the company&#39;s free cash flow. &nbsp;
It&#39;s true that lower interest rates will help reduce the cost to service that debt, but the need to pay down that debt also means that Carvana can&#39;t be that picky when it comes to its customer base. That means it has to try to sell to consumers who may have a higher credit risk even as the risks of lending to those borrowers continue to grow. &nbsp;
<h2>Let History Repeat Itself With CVNA Stock&nbsp;</h2>
The growth in CVNA stock hasn&#39;t come without volatility. At various times in 2024, CVNA stock has dropped sharply, often over 20%. The stock&#39;s relative strength indicator (RSI) was at or near 70 in each case. While RSI isn&#39;t a perfect indicator, it does give investors a guide to a stock&#39;s momentum. And right now, the stock has an RSI of around 68. Plus, by most fundamental measures, Carvana is overvalued.&nbsp;
That suggests that investors should prepare for a pullback in the stock, perhaps a sharp one. That would be the time for investors who have been on the sidelines to get involved.
The article &quot;<a href="https://www.marketbeat.com/originals/analysts-weigh-in-how-will-lower-rates-impact-carvana-stock/">Analysts Weigh In: How Will Lower Rates Impact Carvana Stock?</a>&quot; first appeared on MarketBeat.

Earnings

Large Cap

Technicals

Retail Sales

Markets

Trading Ideas

ALLY

CVNA

Analysts Weigh In: How Will Lower Rates Impact Carvana Stock?

Guggenheim analyst Jonathan Lee maintains Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) with a Buy and raises the price target from $380 to $395.

Guggenheim Maintains Buy on Accenture, Raises Price Target to $395

Unifor Files Notice Of Dispute With CN Early In Negotiations, Representing 3,300 Employees Across Three Collective Agreements Expiring December 31, 2024; CNI Is "Disappointed" That Unifor Is Filing Notice So Early In Process; Committed To Reaching Negotiated Agreements With Union

WIIM

ALMS

Alumis shares are trading lower. The company presented the 28-week open label extension period data from its Phase 2 STRIDE trial of ESK-001.

Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) with a Buy and lowers the price target from $25 to $23.

TVTX

Guggenheim Maintains Buy on Travere Therapeutics, Lowers Price Target to $23

Jony Ive, the iconic former Apple designer known for shaping the look of the iPhone and countless other products, is entering a new venture. And it&#8217;s with <a href="https://www.benzinga.com/news/24/09/40973399/apples-former-design-maestro-jony-ive-confirms-hes-joined-forces-with-openais-sam-altman-for-a-new-a">OpenAI&#8217;s CEO, Sam Altman.</a> This partnership was confirmed in a recent New York Times profile that sheds light on what Ive has been up to since leaving Apple.
Don't Miss:
<ul>
<li>One trailblazing female with an expertise in renewable energy built a company that's bringing the EV revolution to disadvantaged communities —<a href="https://www.benzinga.com/money/dunamis-1"> here&#8217;s how you can invest at just $500</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends<a href="https://www.benzinga.com/money/arrived-private-credit-fund"> would you invest in it</a>?</li>
</ul>
So, what's brewing between these two tech visionaries? Details are still under wraps, but they're cooking up something big in AI. The project is still in its early stages and has a modest team of about 10 people. But don't let the small team size fool you – this crew includes some heavy hitters like Tang Tan and Evans Hankey. These guys are key players who worked with Ive on the iPhone. LoveFrom, Ive's design firm, is at the helm. They're shaping the concept and design of this mysterious new device.
Trending: Teens may never need wisdom teeth removed thanks to this MedTech Company –<a href="https://www.benzinga.com/money/triagenics"> Be an early investor for just $300 for 100 shares!</a>
Ive and Altman reportedly connected through Brian Chesky, the CEO of Airbnb. The Emerson Collective backs their collaboration, Laurene Powell Jobs' venture. The New York Times suggests they could raise up to $1 billion in funding by the end of the year. However, contrary to previous rumors, SoftBank's Masayoshi Son is not mentioned as involved, despite last year's buzz that he might invest $1 billion into the project.
The team is currently working out of a sleek 32,000-square-foot office in San Francisco, part of a $90 million real estate block that Ive acquired. The location hints at the scale of their ambitions, but as for what the actual device will be, well, that's still anyone's guess.
Trending: Groundbreaking trading app with a ‘Buy-Now-Pay-Later' feature for stocks tackles the $644 billion margin lending market –<a href="https://www.benzinga.com/money/wolfpack"> here&#8217;s how to get equity in it with just $500</a>
According to the Times, Ive and Altman have discussed how generative AI could pave the way for a revolutionary new computing device, one that goes beyond what traditional software can do by handling more complex tasks. There were whispers last year that the project might draw inspiration from touch screen technology <a href="https://www.benzinga.com/general/23/12/36256133/steve-jobs-rigged-the-first-iphone-demo-by-faking-full-signal-strength-and-secretly-swapping-devices">and the original iPhone,</a> but nothing is set in stone.
Even LoveFrom's co-founder, Marc Newson, admitted that many details are still in the air. The design, functionality and even the release timeline of the product are all still being worked out. It sounds like we're in for a bit of a wait before this project sees the light of day. But knowing Ive's track record, it's sure to be worth keeping an eye on.
Read Next:
<ul>
<li>Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a></li>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $100.</a></li>
</ul>

Startups

Jony Ive And OpenAI's $1 Billion Bet: A New AI Device In The Works With Just 10 Employees

In the current session, the stock is trading at $23.16, after a 0.13% increase. Over the past month, Kenvue Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>) stock increased by 5.99%, and in the past year, by 14.49%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1727457324_0.png" alt="Past Year Chart" />

<h3>Evaluating Kenvue P/E in Comparison to Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 53.71 in the Personal Products industry, Kenvue Inc. has a lower P/E ratio of 40.58. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1727457324_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

KVUE

P/E Ratio Insights for Kenvue

LENZ

LENZ Therapeutics shares are trading higher after Raymond James initiated coverage on the stock with a Buy rating and announced a price target of $37.

<a href="https://europeancapitalinsights.substack.com/">European inflation </a>reported in France and Spain slowed in September below the European Central Bank's (ECB) target rate of 2%.
This has raised chances of an ECB interest rate cut at its meeting next month.
France's Harmonized Consumer Price Index slowed to 1.5% in September, from 2.2% in August, according to INSEE <a href="https://www.insee.fr/en/statistiques/8259732">data</a>. The consensus for September was 1.9%, according to <a href="https://tradingeconomics.com/france/calendar">TradingView</a>.
"The softest inflation report EVER from France almost smack-dab at our out of consensus forecast," Andreas Steno Larsen, CEO at Steno Research posted on <a href="https://x.com/AndreasSteno/status/1839560122311278737">X</a>. "The ECB will cut in October I think."
French headline annual inflation slowed to 1.2% in France, from 1.8% in August. 
This marked the second straight month that the rate held below the ECB's inflation target, according to INSEE <a href="https://www.insee.fr/en/statistiques/8259732">data</a>.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="848" height="659" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/09/27115744/FrenchInflation.png" alt="" class="wp-image-1530" style="width:624px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/09/27115744/FrenchInflation.png 848w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/09/27115744/FrenchInflation-300x233.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/09/27115744/FrenchInflation-768x597.png 768w" sizes="(max-width: 848px) 100vw, 848px" /></figure>
Source: <a href="https://www.insee.fr/en/statistiques/8259732#graphique-ipc-flash-g1-en">INSEE</a>, France's Consumer Price Index
There was a "big downside surprise" in French headline inflation," Frederik Ducrozet, Head of Macroeconomic Research, Pictet Wealth Management, <a href="https://x.com/fwred/status/1839558166004040025">wrote </a>on X. 
"If we get similar surprises across euro area countries the ECB will have all it needs to cut in October."
Spain&#8217;s annual <a href="https://www.ine.es/dyngs/Prensa/en/adIPC0924.htm">HCPI</a> stood at 1.7%, compared to 2.4% a month earlier, according to the country's statistics institute. This came in below consensus of 1.9%, according to TradingView <a href="https://tradingeconomics.com/spain/calendar">data</a>.&nbsp;&nbsp;
<h3 class="wp-block-heading">European Inflation Boosts Rate Cut Probability to 79%</h3>

Money markets reacted to European inflation data from France and Spain, Europe&#8217;s second and fourth largest economies.
They now indicate that there is a 79% chance of an ECB interest rate cut next month, up from a 60% chance on Thursday and 25% a week ago, the Telegraph <a href="https://www.telegraph.co.uk/business/2024/09/27/ftse-100-markets-latest-news-uk-china-shares-pce-inflation/">reported</a>.&nbsp;
Analysts at BNP Paribas also shifted their call for October to a ECB interest rate cut, as did Bloomberg Economics, according to <a href="https://www.bloomberg.com/news/articles/2024-09-27/french-inflation-plunges-below-2-for-first-time-since-2021">Bloomberg News</a>.
"Our base case has now been revised to call for an ECB rate cut in October,&#8221; Jamie Rush, chief European economist at Bloomberg Economics, <a href="https://www.bloomberg.com/news/articles/2024-09-27/french-inflation-plunges-below-2-for-first-time-since-2021">wrote</a>. 
"We previously expected policymakers to wait on further confirmation of disinflationary trends,&#8221; Rush wrote. &#8220;That confirmation seems to be arriving early."
The euro fell, and Eurozone government bond yields dropped, in response to the European inflation data. Germany&#8217;s <a href="https://www.zawya.com/en/markets/bonds-and-loans/euro-zone-government-bond-yields-drop-after-inflation-data-l1kne1ox">10-year bond yield,</a> the benchmark for the eurozone bloc, fell 3.5 basis points to 2.14%.
<h3 class="wp-block-heading">Lagarde Remains Cautious On European Inflation</h3>
The latest inflation data does not guarantee that the ECB will cut rates.&nbsp;
ECB President Christine Lagarde<a href="https://www.ecb.europa.eu/press/press_conference/monetary-policy-statement/2024/html/ecb.is240912~4f7b17040c.en.html"> cautioned</a> on September 12, after the central bank cut interest rates by 25 basis points, that European inflation is expected to rise again in the latter part of this year before declining towards "our target over the second half of next year." 
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="735" height="350" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/09/27132528/Staffprojections.png" alt="" class="wp-image-1545" style="width:624px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/09/27132528/Staffprojections.png 735w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/09/27132528/Staffprojections-300x143.png 300w" sizes="(max-width: 735px) 100vw, 735px" /></figure>
Euro area HICP inflation: <a href="https://www.ecb.europa.eu/press/projections/html/ecb.projections202406_eurosystemstaff~ee3c69d1c5.en.html">ECB Staff Projections</a>
She also <a href="https://europeancapitalinsights.substack.com/p/lagarde-warns-of-profound-uncertainty?r=3nmatg">warned</a> on September 20 in Washington that the "uncertainty ahead is still profound." Her comments came two days after the Federal Reserve lowered rates by 50 basis points. The ECB first cut rates by 25 basis points in June.
While Lagarde has taken a cautious approach to the ECB's next rate decision, pressure may build on slowing growth across the 27-member bloc. 
German unemployment climbed to 3.8% in August, compared to 3.2% year on year, the country's Federal Statistical Office said on Friday.
"The eurozone is heading towards stagnation," Cyrus de la Rubia, Hamburg Commercial Bank chief economist, said in an S&amp;P Global <a href="https://www.pmi.spglobal.com/Public/Home/PressRelease/cf25d7bb494046ae9256a00ca028f09a">press release</a> on September 23.

Disclaimer:
Any opinions expressed in this article are not to be considered investment advice and are solely those of the authors. European Capital Insights is not responsible for any financial decisions made based on the contents of this article. Readers may use this article for information and educational&nbsp;purposes&nbsp;only.
This article is from an unpaid external contributor. It does not represent Benzinga&#8217;s reporting and has not been edited for content&nbsp;or&nbsp;accuracy.

Eurozone

Economics

European Inflation Drop Raises ECB Rate Cut Chances

A skilled cryptocurrency trader has reportedly made a substantial profit of $392,200 by investing early in MOODENG (CRYPTO: MOODENG), a meme coin inspired by Moo Deng, the adorable baby hippo that has recently <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41062529/memecoin-inspired-by-baby-hippo-moo-deng-jumps-700-since-launch-market-cap-surges-past-190">taken social media by storm</a>.
What Happened: According to <a href="https://x.com/lookonchain/status/1839561317449097619">data</a> from Lookonchain, the trader entered the MOODENG market when its capitalization was a mere $70,000.
The investment has since skyrocketed as the token&#8217;s market cap surged to $244.3 million, according to <a href="https://dexscreener.com/solana/22wrmytj8x2trvqen3fxxi2r4rn6jdhwomtpssmn8rud">data</a> from Dexscreener at the time of writing.
MOODENG, a Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)-based token, has experienced a meteoric rise, mirroring the viral popularity of its namesake. 
Moo Deng, a baby hippo residing in a Thailand zoo, has captured hearts worldwide with her cute mannerisms, drawing long queues of visitors and dominating social media feeds.
The cryptocurrency market, quick to capitalize on viral trends, has seen MOODENG&#8217;s value increase dramatically.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41067493/floki-up-16-as-grafun-meme-coin-launchpad-debuts-on-binance-smart-chain">Floki Up 16% As GraFun Meme Coin Launchpad Debuts On Binance Smart Chain</a>
The token is currently trading at $0.2483, representing an 86.42% increase in the last 24 hours. 
Its total trading volume has reached $59.8 million, with a notably higher buy volume of $30.1 million compared to the sell volume of $29.8 million.
This surge aligns with the broader trend of meme coins gaining traction in the crypto space. MOODENG has outperformed many other tokens on Solana&#8217;s launchpad, Pump.Fun, boasting the highest 24-hour increase among its peers.
The same trader has also demonstrated success with other meme coins, pocketing over $300,000 with trades on little-known Solana meme coins PESTO and OMOCHI.
The news comes as meme coins are experiencing a resurgence, driven by Bitcoin <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41070034/bitcoin-smashes-through-66-000-as-etfs-take-in-365m-to-extend-their-inflow-streak-to-6-str">hitting the $66,000 mark</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41064804/is-kamala-harris-headed-for-a-crypto-reset-advocates-see-encouraging-signs-but-heres-where">Is Kamala Harris Headed For A &#8216;Crypto Reset&#8217;? Advocates See &#8216;Encouraging&#8217; Signs But Here&#8217;s Where It Gets Tricky</a></li>
</ul>
Image: Flickr

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$SOL

Viral Baby Hippo Moo Deng Steals Spotlight From Dogecoin, Shiba Inu: This Trader Made $392,000 With Over 1,000X Meme Coin Return

NuScale Power shares are trading higher after Craig-Hallum initiated coverage on the stock with a Buy rating and announced a $16 price target.

The most recent trading session ended with ODP Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/odp#NYSE">ODP</a>) standing at $28.75, reflecting a +0.49% shift from the previouse trading day&#39;s closing. The stock outpaced the S&amp;P 500&#39;s daily gain of 0.4%. Elsewhere, the Dow saw an upswing of 0.62%, while the tech-heavy Nasdaq appreciated by 0.6%.
Heading into today, shares of the office supply retailer had lost 3.86% over the past month, lagging the Retail-Wholesale sector&#39;s gain of 5.71% and the S&amp;P 500&#39;s gain of 1.71% in that time.
Investors will be eagerly watching for the performance of ODP Corp. in its upcoming earnings disclosure. In that report, analysts expect ODP Corp. to post earnings of $1.49 per share. This would mark a year-over-year decline of 20.74%. Meanwhile, our latest consensus estimate is calling for revenue of $1.83 billion, down 9.13% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates project earnings of $4.29 per share and a revenue of $7.13 billion, demonstrating changes of -23.39% and -8.96%, respectively, from the preceding year.
Investors should also pay attention to any latest changes in analyst estimates for ODP Corp. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company&#39;s business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To capitalize on this, we&#39;ve crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Currently, ODP Corp. is carrying a Zacks Rank of #3 (Hold).
In terms of valuation, ODP Corp. is currently trading at a Forward P/E ratio of 6.68. This expresses a discount compared to the average Forward P/E of 14.34 of its industry.
Also, we should mention that ODP has a PEG ratio of 0.48. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company&#39;s expected earnings growth rate. By the end of yesterday&#39;s trading, the Retail - Miscellaneous industry had an average PEG ratio of 2.3.
The Retail - Miscellaneous industry is part of the Retail-Wholesale sector. This group has a Zacks Industry Rank of 167, putting it in the bottom 34% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
<a href="https://www.zacks.com/stock/news/2342266/odp-corp-odp-laps-the-stock-market-here-s-why?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_6v1-2342266">To read this article on Zacks.com click here.</a>

Small Cap

ODP Corp. Laps the Stock Market: Here's Why

TD Cowen analyst Jason Gabelman maintains TotalEnergies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTE#NYSE">TTE</a>) with a Hold and raises the price target from $72 to $74.

TD Cowen Maintains Hold on TotalEnergies, Raises Price Target to $74

Raymond James initiates coverage on INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) with a Outperform rating and announces Price Target of $18.

INMB

Raymond James Initiates Coverage On INmune Bio with Outperform Rating, Announces Price Target of $18

Each week,&nbsp;Benzinga&#8217;s Stock Whisper Index&nbsp;uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the&nbsp;<a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">surface and deserve attention</a>.
Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance of information to uncover new opportunities and understand why certain stocks should be of interest.
Here's a look at the Benzinga Stock Whisper Index for the week of Sept. 27:
Monolithic Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>): A chipmaker specializing in power management systems saw shares trade higher on the week and interest increase after a <a href="https://www.benzinga.com/quote/MPWR/analyst-ratings">raised price target </a>from Stifel. 
The analyst maintained a Buy rating and raised the price target from $1,000 to $1,100. 
Monolithic <a href="https://www.monolithicpower.com/media/investor-relations/press-releases/Q2_2024_Earnings_Release.pdf">reported </a>second-quarter financial results in August. In the second quarter, revenue was up 15.0% year-over-year to $507.4 million. CEO Michael Hsing highlighted that the results showed the company's transformation from being just a chip supplier "to a full solutions provider."
Monolithic shares were up 3.3% over the last five trading days, as seen on the <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092724&amp;t=be2bearmibe3na1">Benzinga Pro chart </a>below, and are up 53.5% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="999" height="505" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27120223/Screenshot-190.png" alt="" class="wp-image-570182" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27120223/Screenshot-190.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27120223/Screenshot-190-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27120223/Screenshot-190-768x388.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
EMCOR Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EME#NYSE">EME</a>): The electrical and manufacturing construction and facilities services provider gained interest from readers over the week, which could be related to upcoming earnings or the recent Fed rate cut. 
The company is set to report third-quarter financial results in October. Analysts expect the company to report revenue of $3.77 billion and earnings per share of $4.98, up from $3.21 billion and $3.61, respectively, in last year's third quarter. 
EMCOR Group has beaten analyst revenue estimates in 16 straight quarters and earnings per share estimates in nine straight quarters. The recent interest rate cut could prove beneficial to the company as this could lead to increased spending by the private sector.
EMCOR shares were down 2% over the last five trading days, but remain up over 50% year-to-date.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="995" height="502" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27120241/Screenshot-191.png" alt="" class="wp-image-570183" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27120241/Screenshot-191.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27120241/Screenshot-191-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27120241/Screenshot-191-768x387.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
Read Also:&nbsp;<a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40691773/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-august-2024-where-do-tesla-n" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In August 2024 – Where Do Tesla, Nvidia, Apple, AMD Stock Rank?</a>
PDD Holdings Inc &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>): The Chinese commerce company was one of several to enjoy a boost with the country announcing<a href="https://www.benzinga.com/government/24/09/40936014/whats-going-on-with-chinese-tech-stocks-like-alibaba-pdd-on-thursday"> a monetary stimulus</a> to residents. 
Of the Chinese stocks, PDD Holdings saw the largest increase in interest from Benzinga readers over the last week. 
The owner of several commerce platforms in China and Temu in the U.S. could benefit from the stimulus and increased spending in China as it also looks to grow in other international markets.
PDD Holdings shares are up 35% over the last five days, but remain down on a year-to-date basis.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="991" height="497" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27120257/Screenshot-192.png" alt="" class="wp-image-570184" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27120257/Screenshot-192.png 991w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27120257/Screenshot-192-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27120257/Screenshot-192-768x385.png 768w" sizes="(max-width: 991px) 100vw, 991px" /></a></figure>
Vistra Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>): Vistra was one of several energy related companies to see a lift in share price and interest<a href="https://www.benzinga.com/news/24/09/41032700/whats-going-on-with-vistra-stock"> related to a large deal </a>between Constellation Energy and Microsoft. The energy sector, especially companies with exposure to nuclear energy, are seeing rising interest thanks to the growing demand for data centers and AI infrastructure. Vistra has been getting increased attention from analysts in September.
Jefferies <a href="https://www.benzinga.com/quote/VST/analyst-ratings">initiated coverage</a> of the stock with a Buy rating and $99 price target, only to raise its price target to $137 several weeks later. BMO maintained an Outperform rating and raised the price target from $120 to $125. Morgan Stanley maintained an Overweight rating and raised the price target from $110 to $132.
Vistra stock was up 8% over the last week. With a year-to-date gain of over 209%, Vistra is one of the best-performing stocks in 2024.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="997" height="502" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27120317/Screenshot-193.png" alt="" class="wp-image-570185" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27120317/Screenshot-193.png 997w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27120317/Screenshot-193-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27120317/Screenshot-193-768x387.png 768w" sizes="(max-width: 997px) 100vw, 997px" /></a></figure>
GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>): The aerospace giant saw increased interest from readers during the week as shares trade near 52-week highs. The company <a href="https://www.benzinga.com/markets/equities/24/09/40986267/ge-aerospace-takes-flight-with-ai-wingmate-boosts-innovation-employee-productivity-with-microsof">announced the launch </a>of AI Wingmate in collaboration with Microsoft during the week, an initiative that could boost employee productivity.
"The launch of AI Wingmate will transform employee productivity, allowing our people to spend more time solving our customers' toughest problems," GE Aerospace Chief Information Officer David Burns said.
GE Aerospace <a href="https://www.benzinga.com/top-stories/24/08/40531771/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">previously appeared</a> on the Stock Whisper Index thanks to <a href="https://www.benzinga.com/etfs/sector-etfs/24/08/40515453/exclusive-trump-or-harris-12-stocks-2-etfs-could-win-no-matter-whos-president-says-market-strate">increased interest in the defense sector</a> ahead of the 2024 presidential election. Freedom Capital Markets Chief Global Strategist Jay Woods previously told Benzinga the defense stock could be a winner whether its Donald Trump or Vice President Kamala Harris that wins the election.
The aerospace company is set to report third-quarter financial results in October. The company has beaten revenue estimates from analysts in 10 straight quarters and beaten earnings per share estimates from analysts in seven straight quarters.
GE Aerospace shares are up over 80% year-to-date in 2024, with the chart below showing the dip on the week.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="993" height="500" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27120335/Screenshot-194.png" alt="" class="wp-image-570187" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27120335/Screenshot-194.png 993w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27120335/Screenshot-194-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27120335/Screenshot-194-768x387.png 768w" sizes="(max-width: 993px) 100vw, 993px" /></a></figure>
Stay tuned for next week&#8217;s report, and follow Benzinga Pro for all the latest headlines and&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092724&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">top market-moving stories here.</a>
Read the latest Stock Whisper Index reports here:
<ul>
<li><a href="https://www.benzinga.com/exclusives/24/08/40653930/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">August 30</a></li>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40752686/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">September 6</a></li>
<li><a href="https://www.benzinga.com/top-stories/24/09/40855829/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">September 13</a></li>
<li><a href="https://www.benzinga.com/exclusives/24/09/40962321/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">September 20</a></li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40928301/interest-rates-in-free-fall-what-it-means-for-mortgages-credit-cards-and-your-wallet-a">Interest Rates In Free-Fall: What It Means For Mortgages, Credit Cards And Your Wallet As The Federal Reserve Springs Into Action For First Time In 4 Years</a></li>
</ul>

MPWR

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

U.S. stocks reacted positively following the Federal Open Market Committee&#39;s announcement in mid-September that it would lower interest rates by 50 basis points, wider than many analysts had anticipated. Generally, a lower federal funds rate is often a boon for stocks, as businesses are able to more easily secure loans to facilitate growth and consumers may be more likely to increase spending habits.
The Federal Reserve is not the only central bank that has reduced interest rates heading into the final quarter of 2024. Similar institutions in Canada, the U.K., and other countries have begun to trim rates in recent months as well. Notably, the European Central Bank&mdash;the equivalent of the Federal Reserve for the European Union&mdash;cut some interest rates by 25 basis points in June and both deposit facility and refinancing rates in September as well. European stocks may stand to benefit from lower interest rates in the eurozone and, potentially, the U.S. as well.
<h2>IFNNY: Technological Breakthrough and Value Prospect</h2>
Infineon Technologies AG (OTC: <a class="ticker" href="https://www.benzinga.com/stock/ifnnf#OTC">IFNNF</a>) is a German fabricator of semiconductors and related products. With a market capitalization of under $45 billion, it is orders of magnitude smaller than major semiconductor rivals like NVIDIA Corp.&nbsp;or Broadcom Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avgo#NASDAQ">AVGO</a>). Smaller companies often stand to benefit in particular from lowered interest rates as they may be more likely than well-established firms to borrow money in order to finance expansion efforts.
Infineon is, indeed, in the midst of a major project to expand its offerings. The firm announced just days before the latest round of rate cuts that it would emphasize its gallium nitride (GaN) chips thanks to a technological advance that would reduce manufacturing costs. GaN chips are an alternative to popular silicon chips and are known for their light weight, efficiency, and resiliency to high temperatures, among other things.
Infineon&#39;s chips are often used in automotive applications. The automotive industry continues to be plagued by headwinds including supply chain issues and high prices, but Infineon nonetheless remains poised to grow as the automotive industry reverses course. Additionally, the chipmaker&#39;s P/E ratio of 16.3, significantly lower than many other semiconductor companies, gives it an attractive valuation in the meantime.
<h2>NVO: New Drugs in Progress</h2>
Danish healthcare firm Novo Nordisk A/S&nbsp;trades on the New York Stock Exchange, but the international scope of its operations makes it susceptible to changes in interest rates globally. Novo Nordisk has captured headlines around the world with Ozempic, its popular medication used to address type 2 diabetes and obesity concerns.
Now, the firm has at least two more potential blockbuster drugs in various stages of development, and lowered interest rates may play a role in bringing these products to market. First, Wegovy is a weight loss and cardiovascular drug already approved by the FDA in the U.S. that has recently also been backed by the European Medicines Agency. To be sure, Wegovy is already highly successful, but expansion into Europe would help to solidify its blockbuster status.
Second, Novo Nordisk and biotech firm Korro Bio Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/krro#NASDAQ">KRRO</a>) have announced a collaboration seeking to develop two new genetic medicines to treat cardiometabolic disease. The scope of the project is massive, with Korro Bio set to receive up to $530 million to develop and commercialize the new medicines.
<h2>ASML: Large Semiconductor Firm Could Still Grow</h2>
ASML Holdings N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asml#NASDAQ">ASML</a>) is another semiconductor firm, though this one is based in the Netherlands. Despite its size relative to Infineon (it has a market cap of $327 billion), ASML has substantial growth potential.
Analysts have assigned it an average price target of $1,147.80, representing upside potential of 38.6%.
The firm is expected to post earnings growth of more than 63% in upcoming quarters. These factors help to make ASML an attractive prospect even as its P/E ratio is high at 40.8.
<h2>Future Rate Cuts Planned</h2>
The Federal Reserve has already signaled plans to continue to cut rates, and it is possible that the European Central Bank will follow suit. Depending on how these rate cuts are timed and how significant they are, they could help to facilitate a soft landing and continued economic growth or potentially pivot one or more economies into a recession. Thus, despite assurances that additional rate cuts are coming, investors may consider stocking up on shares of companies standing to benefit now.
The article &quot;<a href="https://www.marketbeat.com/stock-ideas/3-stocks-that-could-rise-on-european-bank-interest-rate-cuts/">3 Stocks That Could Rise on European Bank Interest Rate Cuts</a>&quot; first appeared on MarketBeat.

Biotech

Health Care

Offerings

Federal Reserve

General

ASML

AVGO

IFNNF

KRRO

3 Stocks That Could Rise on European Bank Interest Rate Cuts

Macro Notification

iShares MSCI Israel Capped Investable Market Index Fund

ISRA

U.S. Did Not Have Advanced Warning Of Israeli Strike, Defense Secretary Austin Spoke To His Israeli Counterpart As It Was Ongoing

Structure Therapeutics, Inc. Sponsored ADR ( ($GPCR) ) just unveiled an announcement. Structure Therapeutics Inc. has announced strategic changes t...

Structure Therapeutics Announces Key Executive Leadership Changes

Structure Therapeutics appoints new medical chief

Viking, Structure, Terns benefitting from disappointing Novo Nordisk weight loss data

Viking, Structure, Terns benefiting from disappointing Novo Nordisk weight loss data

Terence Flynn, an analyst from Morgan Stanley, has initiated a new Buy rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR). Terence Flynn h...

Buy Rating for Structure Therapeutics: GSBR-1290's Market Potential in Diabesity

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new B...

3 Best Stocks to Buy Now, 9/23/2024, According to Top Analysts

In a report released yesterday, Prakhar Agrawal from Cantor Fitzgerald maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR ...

Cantor Fitzgerald Sticks to Their Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)

Skye stock rallies 22% following weight-loss drug update

Morgan Stanley starts Structure Therapeutics at overweight

Terns Pharmaceuticals: Obesity Advancement Continues With Other Q1 2025 Program Catalyst

ALGS

AMGN

CRBP

GPCR

KROS

MDGL

SKYE

TERN

VKTX

Press Releases

Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290

IPOs

Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants

MAIA Biotechnology (MAIA) to Showcase Groundbreaking Telomere-Targeting Cancer Treatments at BIO International Convention 2024

Qiming's Nisa Leung Made the 2024 Forbes Midas List

Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering

Financing

Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares

Structure Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

Management

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer

Comments

Structure Therapeutics

Interés en corto

Structure Therapeutics (NASDAQ:GPCR) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL